Key facts
- Notable investors include US National Science Foundation, Beta.MN.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Sentrydx
- ·The full record, as it builds
Funding rounds
No funding rounds for Sentrydx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sentrydx
Developer of cancer diagnostic testing technology intended to improve non-invasive detection and monitoring of cancer. The company's platform offers liquid biopsy-based biomarker analysis and diagnostic kits that detect cancer, enabling clinicians to make informed treatment decisions and improve patient monitoring.
- Sector
- Healthcare
- HQ
- Roseville, MN, United States
- Founded
- 2021
- Employees
- 6
- Website
- sentrydx.com/
- Ownership
- Privately Held (backing)
Sentrydx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sentrydx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sentrydx in its N-PORT filings yet. We sweep new filings monthly.